Literature DB >> 15905498

EBV and systemic lupus erythematosus: a new perspective.

Andrew J Gross1, Donna Hochberg, William M Rand, David A Thorley-Lawson.   

Abstract

We have proposed that EBV uses mature B cell biology to access memory B cells as a site of persistent infection. A central feature of this model is that EBV adapts its gene expression profile to the state of the B cell it resides in and that the level of infection is stable over time. This led us to question whether changes in the behavior or regulation of mature B cells would alter the state of EBV persistence. To investigate this, we studied the impact of systemic lupus erythematosus (SLE), a disease characterized by immune dysfunction, on EBV infection. We show that patients with SLE have abnormally high frequencies of EBV-infected cells in their blood, and this is associated with the occurrence of SLE disease flares. Although patients with SLE have frequencies of infected cells comparable to those seen in immunosuppressed patients, in SLE the effect was independent of immunosuppressive therapy. Aberrant expression of viral lytic (BZLF1) and latency (latency membrane proteins 1 and 2a) genes was also detected in the blood of SLE patients. We conclude that the abnormal regulation of EBV infection in SLE patients reflects the sensitivity of the virus to perturbation of the immune system.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15905498     DOI: 10.4049/jimmunol.174.11.6599

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  76 in total

1.  Latency type-dependent modulation of Epstein-Barr virus-encoded latent membrane protein 1 expression by type I interferons in B cells.

Authors:  Daniel Salamon; Monika Adori; Dorina Ujvari; Liang Wu; Lorand L Kis; Harsha S Madapura; Noemi Nagy; George Klein; Eva Klein
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

Review 2.  EBV Persistence--Introducing the Virus.

Authors:  David A Thorley-Lawson
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

3.  Everyone comes from somewhere: systemic lupus erythematosus and Epstein-Barr virus induction of host interferon and humoral anti-Epstein-Barr nuclear antigen 1 immunity.

Authors:  John B Harley; Judith A James
Journal:  Arthritis Rheum       Date:  2010-06

4.  Epstein-Barr virus promotes interferon-alpha production by plasmacytoid dendritic cells.

Authors:  Timothy E Quan; Robert M Roman; Benjamin J Rudenga; V Michael Holers; Joseph E Craft
Journal:  Arthritis Rheum       Date:  2010-06

Review 5.  Epstein-barr virus: environmental trigger of multiple sclerosis?

Authors:  Jan D Lünemann; Thomas Kamradt; Roland Martin; Christian Münz
Journal:  J Virol       Date:  2007-04-25       Impact factor: 5.103

6.  Roles of the TRAF2/3 binding site in differential B cell signaling by CD40 and its viral oncogenic mimic, LMP1.

Authors:  John P Graham; Carissa R Moore; Gail A Bishop
Journal:  J Immunol       Date:  2009-08-10       Impact factor: 5.422

7.  TRAF6 is a critical regulator of LMP1 functions in vivo.

Authors:  Kelly M Arcipowski; Laura L Stunz; Gail A Bishop
Journal:  Int Immunol       Date:  2013-10-29       Impact factor: 4.823

8.  Infection in systemic lupus erythematosus: friend or foe?

Authors:  Lisa Francis; Andras Perl
Journal:  Int J Clin Rheumtol       Date:  2010-02-01

9.  Human complement receptor type 1/CD35 is an Epstein-Barr Virus receptor.

Authors:  Javier G Ogembo; Lakshmi Kannan; Ionita Ghiran; Anne Nicholson-Weller; Robert W Finberg; George C Tsokos; Joyce D Fingeroth
Journal:  Cell Rep       Date:  2013-02-14       Impact factor: 9.423

10.  Antineutrophil Cytoplasmic Autoantibody Associated Systemic Vasculitis Is Associated with Epstein - Barr virus in the Setting of HIV Infection.

Authors:  Mehdi Mirsaeidi; Fatima Syed; Elaine S Jaffe
Journal:  Infect Dis Clin Pract (Baltim Md)       Date:  2013-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.